Who is sponsoring NCT04218422?

NCT04218422 is sponsored by Wayne State University.

What drugs are being tested in NCT04218422?

Interventions in NCT04218422: Battlefield Acupuncture, Sham Acupuncture.

What condition does NCT04218422 study?

NCT04218422 studies Hidradenitis Suppurativa.

Is NCT04218422 still recruiting?

NCT04218422 is currently recruiting now. Last updated 16 May 2023.

Last reviewed 2023-05-16 · How we verify

NCT04218422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Battlefield Acupuncture for Pain in Hidradenitis Suppurativa

Recruiting now NA Last updated 16 May 2023

What this trial tests

NA trial testing Battlefield Acupuncture in Hidradenitis Suppurativa in 32 participants. Currently enrolling.

Timeline

22 January 2020

Primary endpoint
23 December 2030

20 February 2031

Quick facts

Lead sponsor	Wayne State University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	32
Start date	22 January 2020
Primary completion	23 December 2030
Estimated completion	20 February 2031
Sites	1 location across United States

Drugs / interventions tested

Battlefield Acupuncture
Sham Acupuncture

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Wayne State University

Who can join

18 and older, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will investigate battlefield acupuncture as a treatment for the pain of hidradenitis suppurativa.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hidradenitis Suppurativa: Where We Are and Where We Are Going.
Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, et al · · 2021 · cited 85× · PMID 34440863 · DOI 10.3390/cells10082094
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa-Part II: Procedural and Wound Care Therapies.
Fragoso NM, Masson R, Gillenwater TJ, Shi VY, et al · · 2023 · cited 3× · PMID 37402030 · DOI 10.1007/s13555-023-00957-5

Verify or expand the search:

Other trials of Battlefield Acupuncture

Trials testing the same drug.

NCT06128772 — Utilizing Battlefield Acupuncture to Treat Chronic Pain · NA · recruiting
NCT07528300 — Effect of Battlefield Acupuncture on Pain Control During Inpatient Treatment of Exertional Rhabdomyolysis · NA · recruiting
NCT05417724 — Utilizing Battlefield Acupuncture(BFA) to Treat Chronic Pain for Homeless and at Risk Veterans. · NA · completed
NCT04236908 — Accessible Acupuncture for the Warrior With Acute Low Back Pain · NA · completed
NCT04094246 — Battlefield Acupuncture Following Shoulder Surgery · NA · completed

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other Wayne State University trials

Trials by the same sponsor.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04218422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wayne State University
Last refreshed: 16 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04218422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing